-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Nonmelanomatous Skin Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Nonmelanomatous Skin Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Nonmelanomatous Skin Cancer Drug Details: RP-1 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Transitional Cell Carcinoma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Merkel Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Merkel Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Merkel Cell Carcinoma Drug Details: RP-1...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vusolimogene Oderparepvec in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vusolimogene Oderparepvec in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vusolimogene Oderparepvec in Cutaneous Squamous Cell Carcinoma...
-
Company Insights
Innovation and Patenting activity of Plains GP Holdings LP Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Plains GP Holdings LP Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GP-2250 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GP-2250 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GP-2250 in Pancreatic Cancer Drug Details:GP-2250 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GP-2250 in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GP-2250 in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GP-2250 in Metastatic Adenocarcinoma of The Pancreas Drug Details:GP-2250 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-521 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AB-521 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AB-521 in Solid Tumor Drug Details: AB-521 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GP-01CR01 in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GP-01CR01 in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GP-01CR01 in Multiple Myeloma (Kahler Disease)Drug Details:GP01CR01 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AB-521 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AB-521 in Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AB-521 in Renal Cell Carcinoma Drug Details: AB-521 is under...